01061.HK
Essex Bio-Technology Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.21
+3.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.5B | 1.8B | 1.7B | 1.7B | 1.3B |
| Cost of Revenue | 408.5M | 195.9M | 171.2M | 167.3M | 128.4M |
| Gross Profit | 3.0B | 1.6B | 1.5B | 1.5B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 83.4M | 42.7M | 29.8M | 39.1M | 41.6M |
| SG&A Expense | 2.3B | 1.2B | 1.1B | 1.2B | 914.2M |
| General & Admin Expense | 461.2M | 223.2M | 213.9M | 217.0M | 156.0M |
| Selling & Marketing Expense | 1.9B | 984.2M | 934.2M | 1.0B | 758.2M |
| Other Expenses | (25.9M) | — | — | (39.1M) | (47.9M) |
| Total Operating Expenses | 2.4B | 1.3B | 1.2B | 1.2B | 907.9M |
| Cost and Expenses | 2.8B | 1.4B | 1.3B | 1.4B | 1.1B |
| Operating Income (EBIT) | 664.9M | 367.8M | 320.7M | 310.3M | 273.0M |
| Non-Operating | |||||
| Interest Income | 24.0M | 11.8M | 11.4M | 12.3M | 8.9M |
| Interest Expense | 15.1M | 7.8M | 6.1M | 11.2M | 11.5M |
| Net Interest Income | 8.9M | 4.0M | 5.4M | 1.1M | (2.6M) |
| Other Non-Op Income/Expense | 75.8M | 46.9M | 54.8M | 35.7M | (12.6M) |
| Non-Operating Income (excl Interest) | (61.9M) | (49.0M) | (34.1M) | (48.5M) | (38.5M) |
| EBT (Pre-Tax Income) | 741.7M | 414.7M | 375.5M | 346.0M | 260.3M |
| Income Tax Expense | 162.2M | 96.6M | 68.3M | 70.8M | 34.9M |
| Bottom Line | |||||
| Net Income | 578.6M | 318.1M | 307.2M | 275.3M | 225.4M |
| Earnings from Cont. Ops | 578.6M | 318.1M | 307.2M | 275.3M | 225.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 578.6M | 318.1M | 309.7M | 279.4M | 229.5M |
| Per Share | |||||
| Basic EPS | HK$1.02 | HK$0.56 | HK$0.54 | HK$0.49 | HK$0.39 |
| Diluted EPS | HK$1.02 | HK$0.56 | HK$0.53 | HK$0.47 | HK$0.38 |
| Revenue Per Share | HK$6.10 | HK$3.20 | HK$2.94 | HK$2.99 | HK$2.30 |
| Shares | |||||
| Basic Shares Outstanding | 567.0M | 567.0M | 567.5M | 570.2M | 574.0M |
| Diluted Shares Outstanding | 567.0M | 567.0M | 582.3M | 595.6M | 599.4M |
| Profitability Metrics | |||||
| EBITDA | 836.8M | 467.9M | 400.7M | 418.4M | 313.5M |
| D&A | 109.9M | 51.1M | 45.9M | 59.5M | 41.5M |
| EBIT | 726.9M | 416.8M | 354.8M | 358.9M | 272.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026